Jul 14, 2026 06:01AM
Jul 14, 2026 06:00AM
Oct 21, 2025 07:00AM
Oct 9, 2025 06:02AM
Oct 9, 2025 06:01AM
Jun 13, 2025 11:43AM
May 13, 2025 04:52AM Akero Therapeutics (AKRO) PT Lowered to $78 at Citi
May 5, 2025 09:51AM
Mar 24, 2025 09:13AM
Jan 28, 2025 05:02AM
Dec 19, 2024 02:00PM
Oct 20, 2024 10:00AM
Aug 1, 2024 08:00AM
Jun 5, 2024 04:18PM AKRO STOCKHOLDERS - Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Akero Therapeutics, Inc. Class Action
May 16, 2024 04:15PM
May 7, 2024 03:06PM
May 2, 2024 01:30PM
Apr 30, 2024 12:42AM
Apr 22, 2024 06:11AM
Feb 29, 2024 07:00AM
Dec 18, 2023 07:00AM Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
Nov 13, 2023 07:00AM
May 15, 2023 07:00AM
Mar 29, 2023 04:01PM
Mar 29, 2023 04:01PM
Mar 29, 2023 04:01PM
Dec 21, 2022 04:01PM
Dec 21, 2022 04:01PM Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones
Dec 19, 2022 10:36AM
Dec 8, 2022 07:02AM
Dec 8, 2022 07:00AM
Dec 8, 2022 07:00AM
Nov 15, 2021 06:14AM
Nov 12, 2021 08:01AM
Nov 12, 2021 08:01AM Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological Improvement in EFX-treated NASH Patients after 16 Weeks of Treatment
Nov 12, 2021 08:01AM
Nov 12, 2021 07:00AM
Nov 12, 2021 07:00AM
Oct 20, 2021 09:27AM
Oct 19, 2021 06:04PM
Oct 19, 2021 04:15PM
Oct 19, 2021 04:15PM Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH
Oct 19, 2021 04:15PM
Mar 23, 2021 08:02AM
Mar 23, 2021 08:00AM
Mar 23, 2021 08:00AM
Mar 22, 2021 04:03PM
Mar 22, 2021 04:01PM
Mar 22, 2021 04:01PM Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C
Mar 16, 2021 08:00AM

325,998 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All